Nephros, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value and what the price assumes
Average of FY2023–FY2024 (cash from operations less capital spending), from the statements below.
Starts at revenue growth over the last three years, 23.5% a year (statements).
US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).
Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.
Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.
Debt or cash not on file: 0 to start with.
What today's price assumes
A market value of $36 M means free cash flow growing 48.6% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.
Revenue grew 23.5% a year over the last three years.
Against the market value, for other rates
Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.
| Discount rate ↓ / growth → | 18.48% | 20.98% | 23.48% | 25.98% | 28.48% |
|---|---|---|---|---|---|
| 7.92% | -82% | -78% | -73% | -68% | -61% |
| 8.92% | -85% | -82% | -78% | -74% | -69% |
| 9.92% | -87% | -85% | -82% | -78% | -74% |
| 10.92% | -89% | -87% | -85% | -82% | -78% |
| 11.92% | -91% | -89% | -87% | -84% | -81% |
On one scale
Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.
Your own DCF model
A full discounted-cash-flow model of Nephros, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Medical Instruments
Multiples of its companies with a market value at most 60 days old, times Nephros, Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | Nephros, Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| P/E | 24.5× / 42.4× / 61.3× | 18.7× | net income $1 M | $29 M to $73 M | 15 |
| Price to sales | 2.0× / 3.5× / 6.6× | 1.6× | revenue $19 M | $37 M to $125 M | 23 |
| Price to book | 2.0× / 4.4× / 6.6× | 3.5× | book equity $10 M | $20 M to $67 M | 23 |
Against its own history
Nephros, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
P/E
20.5×Now below its median of 39.0×, in the bottom quarter of its range; range 20.5× to 286.2× over 19 months.
Price to sales
1.7×Now below its median of 2.3×; range 1.1× to 13.5× over 29 months.
Price to book
3.5×Now below its median of 4.4×; range 0.9× to 20.3× over 29 months.
As of Oct 30, 2026
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $19 M | $1 M | $2 M | — | — | — | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $14 M | $0 M | $-0 M | $0 M | $-1 M | — | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $14 M | $-2 M | $1 M | $0 M | $1 M | — | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $10 M | $-7 M | $-3 M | $0 M | $-3 M | $-4 M | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $10 M | $-4 M | $-1 M | $0 M | $-1 M | $-7 M | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $9 M | $-5 M | $-7 M | $0 M | $-7 M | $-8 M | SEC annual report (10-K, 20-F) |